References

AG Freifeld, EJ Bow, KA Sepkowitz et al. Clinical Practice Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Disease Society of America. Clinical Infectious Diseases 2011;52(4):e56-e93

Alberta Health Services Clinical Practice Guideline. Management of Febrile Neutropenia in Adult Cancer Patients 2014. Available here

BC Cancer Agency Empiric Treatment of Febrile Neutropenia 2015. Available here

Sunnybrook Health Sciences Febrile Neutropenia Guideline 2016. Available here

J de Naurois, I Novitzky-Basso, MJ Gill, F Marti Marti, MH Cullen and F Roila. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Annals of Oncology 2010;21(Supp 5):v252–v256.

P Villafuerte-Gutierrez, L Villalon, JE Losa, and C Henriquez-Camacho. Treatment of Febrile Neutropenia and Prophylaxis in Hematologic Malignancies: A Critical Review and Update. Advances in Hematology 2014. Article ID 986938, 9 pages. doi:10.1155/2014/986938

J Gea-Banacloche. Evidence-based approach to treatment of febrile neutropenia in hematological maliganices. Hematology 2013. Available here

Vidal L, Ben dor I, Paul M, Eliakim-Raz N, Pokroy E, Soares-Weiser K, Leibovici L. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No.: CD003992. DOI: 10.1002/14651858.CD003992.pub3

Paul M, Yahav D, Bivas A, Fraser A, Leibovici L. Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams. Cochrane Database of Systematic Reviews2010, Issue 11. Art. No.: CD005197. DOI: 10.1002/14651858.CD005197.pub3.

Paul M, Dickstein Y, Schlesinger A, Grozinsky-Glasberg S, Soares-Weiser K, Leibovici L. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia. Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD003038. DOI: 10.1002/14651858.CD003038.pub2.

Cancer Care Ontario GCSF Recommendations 2016. Available here

CL Bennett, B Djulbegovic, LB Norris, and JO Armitage. Colony-Stimulating Factors for Febrile Neutropenia during Cancer Therapy. N Engl J Med 2013; 368:1131-1139.

MS Aapro, J Bohlius, DA Cameron et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011;47(1):8-32. Available here

T Smith, K Bohlke, G Lyman, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2015;33(28)3199-212.